For a quarter century, Drug Development & Delivery has connected innovators, scientists, and industry leaders while spotlighting the technologies and ideas shaping the future of the industry. We celebrate 25 years of advancing the conversation!
In this case study, OSDPredict™ narrowed formulation options early, focusing development on the most viable strategies which reduced experimental burden and conserved valuable materials.
As clinical trials become increasingly digitally enabled, organizations must look beyond successful technology deployment to determine whether new tools are delivering measurable value. This article presents a five-layer framework for evaluating technical fitness, workflow integration, adoption, data reliability, and operational outcomes to help translate clinical technology investments into better trial execution and evidence.
AstraZeneca and Novo Nordisk have both committed to science-based net-zero across their full value chains by 2045. However, decarbonizing manufacturing alone leaves most of the footprint untouched. Meeting these net-zero targets requires changes to the products themselves, the devices that deliver them, and the systems built around them, including the reprocessing and reuse networks. The route to a more sustainable device is not the same for every product, and the single biggest determinant of what is achievable is where a device sits in its product development lifecycle when sustainability is first considered.
Cindy H. Dubin speaks with injection device developers about creating devices that are intelligent, intuitive, patient-centric systems that make advanced therapies easier, safer, and more accessible to use at home.
As sustainability expectations continue to rise across the pharmaceutical industry, drug makers, CDMOs, and equipment suppliers are under increasing pressure to reduce waste, energy use, and environmental impact. Find out in this exclusive Drug Development & Delivery eBook how companies like Bespak have taken steps to support the scale of commercial-scale manufacturing of a low-carbon Pressurized Metered Dose Inhaler. Additionally, learn how Aptar Pharma Injectables division has undertaken an effort to identify the principal sources of emissions across its elastomeric closure solutions. Finally, a new sustainability report reveals what the pharma industry is doing particularly well – and not so well – in its sustainability endeavors.
Advances in inhaled drug delivery are improving how therapies reach the lungs, with innovations in formulations, devices, biologics, and digital tools helping expand treatment options for respiratory diseases.
Over the past 25 years, we have witnessed extraordinary change – from advances in drug discovery and delivery technologies to the rise of biologics, personalized medicine, new therapeutic modalities, and an increasingly connected global marketplace. The way our industry innovates has changed.
Abzena is the leading end-to-end CDMO + CRO for bioconjugates (ADCs, AOCs, RDCs), and complex biologics. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor our strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule.
Large-Scale LNP Process Conversions: The many hurdles of LNP scale-up and what to consider
Lipid nanoparticle (LNP) formulation development begins on a small scale, often with homemade or benchtop setups, using syringe pumps and easily accessible micro-mixing systems. Once …
Sustained release drug delivery is rapidly expanding across respiratory, ophthalmic, transdermal, and implantable applications, but translating products from development to manufacturing remains both complex and costly. Programs can stall due to material–drug compatibility issues, inconsistent release profiles, tooling-related variability, and …
A technology agnostic approach based on a fundamental understanding of API properties, a well-defined yet flexible target product profile, and a mindset for scalability and commercial relevance leads to success in formulation development and drug product design.
In this whitepaper, …
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
October 7 – Prefilled Syringes
October 14 – Injection Devices
October 21 – Transdermal/Topical Delivery
October 28 – Formulation Development